Private company

Peak Bio, Inc.

In its 2024 annual report the company says: “Peak Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics addressing significant unmet need in the areas of cancer, inflammatory and rare diseases.”3 It is headquartered in Pleasanton, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersPleasanton, California1
  • Incorporated inDE2
  • Business address4900 Hopyard Road, Suite 100, Pleasanton, Ca 945882
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Peak Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics addressing significant unmet need in the areas of cancer, inflammatory and rare diseases. We will continue to explore and partner with researchers, clinicians, patient advocacy groups, academic institutions, governmental agencies, and our investors to continue to expand treatment options and partnerships to meet those expectations.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3551.6%Operating margin4
-3486.5%Net margin4
-39.5%Revenue growth, 20234
-$4.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development37¢$1.6M
  • Interest63¢$2.7M

Out of $367.9K in revenue.4 The company lost money this year.

Financial statements

Revenue54$367.9K in 2023−30% since 2021
0$200.0K$400.0K$600.0K$800.0K2021: $528.3K$528.3K20212022: $607.7K$607.7K2022+15%2023: $367.9K$367.9K2023−39%
Operating income54-$13.1M in 2023+44% since 2021
-$15.0M-$10.0M-$5.0M02021: -$9.1M-$9.1M20212022: -$11.8M-$11.8M2022+31%2023: -$13.1M-$13.1M2023+10%
Net income64-$12.8M in 2023+55% since 2021
-$15.0M-$10.0M-$5.0M02021: -$8.3M-$8.3M20212022: -$13.1M-$13.1M2022+58%2023: -$12.8M-$12.8M2023−2%
Fiscal year2020202120222023
Revenue$528.3K5$607.7K4$367.9K4
Research and development$7.1M5$3.9M4$1.6M4
Operating expenses$9.6M5$12.5M4$13.4M4
Operating income-$9.1M5-$11.8M4-$13.1M4
Interest$11.5K5$48.0K4$2.7M4
Income before tax-$8.2M5-$13.2M4-$12.8M4
Income tax$82.1K5-$74.0K4$04
Net income-$8.3M6-$13.1M4-$12.8M4
Earnings per share-$0.485-$0.744-$0.614
Earnings per share (diluted)-$0.485-$0.744-$0.614
Shares (weighted, basic)17.2M shares517.7M shares421.2M shares4
Shares (weighted, diluted)17.2M shares517.7M shares421.2M shares4

Compare Peak Bio, Inc. with another company

Corporate structure

Peak Bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Peak Bio, Inc.

  • SBI INVESTMENT KOREA CO., LTD. Filed SC 13G/A on Peak Bio, Inc., latest Dec 4, 2024 (2 filings since Feb 28, 2023)
  • Hoyoung Huh Filed SC 13D on Peak Bio, Inc., latest Mar 21, 2023
  • Vellar Opportunities Fund Master, Ltd. Filed SC 13G/A on Peak Bio, Inc., latest Feb 14, 2023 (2 filings since Aug 31, 2022)
  • James E. Flynn Filed SC 13G/A on Peak Bio, Inc., latest Feb 10, 2023 (2 filings since Feb 11, 2022)
  • Phillip Et Al Frost Md. Filed SC 13G/A on Peak Bio, Inc., latest Feb 3, 2023
  • Steven Michael Oliveira Filed SC 13G/A on Peak Bio, Inc., latest May 9, 2022
  • Saba Capital Management, L.P. Filed SC 13G on Peak Bio, Inc., latest Feb 4, 2022
  • K2 PRINCIPAL FUND, L.P. Filed SC 13G/A on Peak Bio, Inc., latest Jan 26, 2022 (2 filings since Jan 5, 2022)
  • Peak Bio, Inc. Pleasanton, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Peak Bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$752.9K4 Dec 31, 2023$848.3K4 Dec 31, 2022−11.2%
Accumulated depreciation$599.8K4 Dec 31, 2023$471.6K4 Dec 31, 2022+27.2%
Property and equipment, net$153.1K4 Dec 31, 2023$376.6K4 Dec 31, 2022−59.3%
Operating-lease assets (leased space)$04 Dec 31, 2023$3.7M4 Dec 31, 2022−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$381.6K4 Dec 31, 2023$654.9K4 Dec 31, 2022−41.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$05 Dec 31, 2022

Leadership

Who has led Peak Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David I. Rosenberg2021
  2. David J. Strupp2021

Chief financial officer

  1. Timothy M. Cunningham2022
2025
Board members and other officers (14)

Former names

  • Ignyte Acquisition Corp.Dec 9, 2020 to Nov 2, 20222

Timeline

  1. Nov 14, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Change to shareholders' rights23
  2. Nov 7, 20248-K Shareholder vote24
  3. Sep 30, 20248-K Entered a material agreement; Unregistered sale of shares; Executive or director change25
  4. Sep 3, 20248-K Executive or director change26
  5. Aug 14, 20248-K Executive or director change27
  6. Jul 24, 20248-K Executive or director change28
  7. Jul 17, 20248-K Entered a material agreement; Unregistered sale of shares29
  8. Jun 7, 20248-K Entered a material agreement; Unregistered sale of shares30
  9. Mar 5, 20248-K Entered a material agreement; Bylaws or fiscal year changed; Regulation FD disclosure31
  10. Feb 21, 20248-K Unregistered sale of shares32
  11. Feb 6, 20248-K Unregistered sale of shares33
  12. Jan 29, 20248-K Entered a material agreement34
  13. Mar 12, 2021New chief executive David J. Strupp becomes CEO11
  14. Jan 27, 2021New chief executive David I. Rosenberg becomes CEO10

Filings

158 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 39 major events, 33 insider forms, 12 large holders, 61 other. The latest 20:

  1. Dec 4, 2024SC 13G/A SCHEDULE 13G/A EDGAR
  2. Dec 4, 20244 EDGAR
  3. Nov 18, 20244 EDGAR
  4. Nov 18, 20244 EDGAR
  5. Nov 18, 20244 EDGAR
  6. Nov 15, 2024EFFECT EDGAR
  7. Nov 15, 202415-12G EDGAR
  8. Nov 14, 2024POS AM EDGAR
  9. Nov 14, 20248-K EDGAR
  10. Nov 12, 202410-Q EDGAR
  11. Nov 7, 20248-K EDGAR
  12. Oct 11, 2024DEFM14A EDGAR
  13. Sep 30, 20248-K EDGAR
  14. Sep 3, 20248-K EDGAR
  15. Aug 23, 202410-Q EDGAR
  16. Aug 23, 202410-Q EDGAR
  17. Aug 14, 2024NT 10-Q EDGAR
  18. Aug 14, 20248-K EDGAR
  19. Aug 6, 202410-K EDGAR
  20. Jul 24, 20248-K EDGAR

The 158 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 20 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 27, 2023LaMond Stephen JSee RemarksBuy2,600Form 4
Sep 26, 2023LaMond Stephen JSee RemarksBuy3,000Form 4
Sep 21, 2023Huh HoyoungDirectorBuy45,000Form 4
Sep 20, 2023Huh HoyoungDirectorBuy30,000Form 4
Sep 19, 2023Huh HoyoungDirectorBuy50,000Form 4
Sep 18, 2023LaMond Stephen JSee RemarksBuy2,500Form 4
Sep 18, 2023LaMond Stephen JSee RemarksBuy2,500Form 4
Sep 15, 2023LaMond Stephen JSee RemarksBuy11,750Form 4
Sep 15, 2023LaMond Stephen JSee RemarksBuy26,000Form 4
Sep 15, 2023Huh HoyoungDirectorBuy25,000Form 4
Sep 14, 2023Huh HoyoungDirectorBuy20,000Form 4
Sep 13, 2023Huh HoyoungDirectorBuy30,000Form 4
Sep 12, 2023Huh HoyoungDirectorBuy17,000Form 4
Sep 11, 2023Huh HoyoungDirectorBuy30,000Form 4
Aug 31, 2023Huh HoyoungDirectorBuy0Form 4
Aug 31, 2023Huh HoyoungDirectorBuy13,000$0.27$3.5KForm 4
Aug 30, 2023Huh HoyoungDirectorBuy0Form 4
Aug 30, 2023Huh HoyoungDirectorBuy74,750$0.26$19.5KForm 4
Aug 29, 2023Huh HoyoungDirectorBuy0Form 4
Aug 29, 2023Huh HoyoungDirectorBuy5,500$0.25$1.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Peak Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPeak Bio, Inc.1
  • CIK0001834645
  • Employer ID (EIN)85-24481571
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4900 Hopyard Road, Suite 100, Pleasanton, CA 945881
  • Phone(925) 463-48001
  • Shares outstanding23,124,888 as of Nov 12, 20248
  • Public float$17.0M as of Jun 30, 20234
  • On EDGAR sinceDec 9, 20201
  • Filings191 in all: 8-K (41), 4 (24), 3 (16), 10-Q (12), UPLOAD (12), CORRESP (10), NT 10-Q (8), SC 13G/A (8)1
    All 33 form types

    PRER14A (7), SC 13G (7), 10-K (4), 424B3 (4), EFFECT (4), 8-K/A (3), NT 10-K (3), POS AM (3), S-1/A (3), 25-NSE (2), 4/A (2), 425 (2), DEFA14A (2), DEFM14A (2), S-1 (2), 10-K/A (1), 15-12G (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS (1), PRE 14A (1), PREM14A (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Aug 6, 2024
    Quarterly report (10-Q) Nov 12, 2024
    Proxy statement (DEF 14A) Oct 19, 2022
    Latest 8-K (8-K) Nov 14, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42